NO20003414D0 - Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi - Google Patents

Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi

Info

Publication number
NO20003414D0
NO20003414D0 NO20003414A NO20003414A NO20003414D0 NO 20003414 D0 NO20003414 D0 NO 20003414D0 NO 20003414 A NO20003414 A NO 20003414A NO 20003414 A NO20003414 A NO 20003414A NO 20003414 D0 NO20003414 D0 NO 20003414D0
Authority
NO
Norway
Prior art keywords
ppar
ypsilon
dermatology
activators
anomaly
Prior art date
Application number
NO20003414A
Other languages
English (en)
Other versions
NO325171B1 (no
NO20003414L (no
Inventor
Michel Rivier
Irina Safonova
Serge Michel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of NO20003414D0 publication Critical patent/NO20003414D0/no
Publication of NO20003414L publication Critical patent/NO20003414L/no
Publication of NO325171B1 publication Critical patent/NO325171B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20003414A 1997-12-31 2000-06-29 Anvendelse av minst en aktivator av reseptorer av PPAR-gamma type for fremstilling av et farmasoytisk, mer spesielt dermatologisk, preparat. NO325171B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716808A FR2773075B1 (fr) 1997-12-31 1997-12-31 Utilisation d'activateurs de ppar-gamma en dermatologie
PCT/FR1998/002894 WO1999034783A1 (fr) 1997-12-31 1998-12-28 UTILISATION D'ACTIVATEURS DE PPAR-η EN DERMATOLOGIE

Publications (3)

Publication Number Publication Date
NO20003414D0 true NO20003414D0 (no) 2000-06-29
NO20003414L NO20003414L (no) 2000-08-31
NO325171B1 NO325171B1 (no) 2008-02-11

Family

ID=9515385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003414A NO325171B1 (no) 1997-12-31 2000-06-29 Anvendelse av minst en aktivator av reseptorer av PPAR-gamma type for fremstilling av et farmasoytisk, mer spesielt dermatologisk, preparat.

Country Status (13)

Country Link
US (1) US6403656B1 (no)
EP (1) EP1041977B1 (no)
JP (1) JP3773790B2 (no)
AT (1) ATE402698T1 (no)
AU (1) AU745187B2 (no)
BR (1) BR9815340A (no)
CA (1) CA2314607C (no)
DE (1) DE69839815D1 (no)
ES (1) ES2310019T3 (no)
FR (1) FR2773075B1 (no)
NO (1) NO325171B1 (no)
NZ (1) NZ505089A (no)
WO (1) WO1999034783A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
JP2004536018A (ja) * 2000-07-31 2004-12-02 バル・イラン・ユニバーシティ 創傷治療のための方法および薬学的組成物
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
EP1331934B1 (de) * 2000-11-09 2006-03-29 Phenion GmbH &amp; Co KG Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20070086967A1 (en) * 2003-12-03 2007-04-19 Brian Macdonald Treatment of psoriasis with rosiglitazone
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
KR100702415B1 (ko) * 2006-03-03 2007-04-09 안웅식 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
US20090291986A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
US20090291066A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas composition and method of treating facial skin defect
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EA020856B1 (ru) 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
AR073505A1 (es) * 2009-09-10 2010-11-10 Monte Verde S A Composiciones y metodos para el tratamiento de enfermedades proliferativas
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US20110274775A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Extracts of southernwood and topical uses thereof
US20110274776A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Compositions comprising extracts of southernwood and an amine compound
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
FR3049864A1 (fr) 2016-04-06 2017-10-13 Naturex Extrait vegetal issu d'une plante du genre aerva, composition le contenant et utilisation dudit extrait vegetal
EP3921299B1 (en) 2019-02-08 2024-11-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
IT202000027489A1 (it) * 2020-11-17 2022-05-17 Mauro Michele Maria Picardo Attivatori selettivi dei recettori attivati da proliferatori peroxisomiali (PPARs) per il trattamento della vitiligine
CN116548385B (zh) * 2023-04-20 2023-10-27 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 自发型系统性红斑狼疮动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014824A1 (en) * 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5443844A (en) * 1992-12-03 1995-08-22 Mcdaniel; William R. Linoleic acid preparations for topical treatment of acne vulgaris
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1998008089A1 (en) * 1996-08-23 1998-02-26 Arch Development Corporation Identification of activators and inhibitors of sebum formation
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
EP1019059A4 (en) * 1997-01-24 2004-01-14 Univ California USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Also Published As

Publication number Publication date
EP1041977A1 (fr) 2000-10-11
CA2314607A1 (fr) 1999-07-15
EP1041977B1 (fr) 2008-07-30
JP2002500179A (ja) 2002-01-08
BR9815340A (pt) 2000-10-31
WO1999034783A1 (fr) 1999-07-15
NO325171B1 (no) 2008-02-11
NO20003414L (no) 2000-08-31
FR2773075B1 (fr) 2000-05-05
DE69839815D1 (de) 2008-09-11
NZ505089A (en) 2002-12-20
ES2310019T3 (es) 2008-12-16
JP3773790B2 (ja) 2006-05-10
AU745187B2 (en) 2002-03-14
US6403656B1 (en) 2002-06-11
FR2773075A1 (fr) 1999-07-02
CA2314607C (fr) 2009-02-03
AU2057599A (en) 1999-07-26
ATE402698T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
NO20003414L (no) Anvendelse av PPAR-&lt;ypsilon&gt; aktivatorer i dermatologi
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
ATE134368T1 (de) Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
TR200102800T2 (tr) Yeni bileşikler.
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
DE59709414D1 (de) Oxyiminopregnancarbolactone
EP0786995A4 (no)
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
ATE284853T1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
UA42795C2 (uk) Протизапальний засіб для зовнішнього застосування, що містить німесулід, і спосіб його одержання
DE60045508D1 (de) Dalda-analoge und ihre verwendung
TR200100426T2 (tr) Nematisit pirazoller
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ATE206708T1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
DE69803383D1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
TR199900662T2 (xx) 1-Hidroksi-2-piridonlar�n seborik dermatit tedavisi amac�yla kullan�m�
BR9611947A (pt) Isoindolonas fundidas como inibidores da quinase da proteina c

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees